Fig. 1 · Structure

Documents & Downloads

Oroxylin A

Cat. No. A14367 CAS 480-11-5
Oroxylin A is an O-methylated flavone, It has demonstrated activity as a dopamine reuptake inhibitor and is also a negative allosteric modulator of the benzodiazepine site of the GABAA receptor.

In Stock

Publications for Oroxylin A

3 publications citing this product

  1. Paramesha Bugga, .et al. , Cell Signal, 2022, Jun;94:110309 PMID: 35304284
  2. Bugga Paramesha, .et al. , Antioxidants (Basel), 2021, Feb 24;10(3):338 PMID: 33668369
  3. Mai Nagasaka, .et al. , Molecules, 2018, Jun; 23(6): 1394 PMID: 29890668

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In LX2 hepatic stellate cells, oroxylin A reduced LDH-A expression and intracellular activity after 24 hours. These cellular findings support an effect on glycolytic regulation; they do not establish direct enzyme binding or a biochemical IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
HCT-116 IC50 33.9 μM Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay [PMID: 22196122]
HepG2 IC50 22.7 μM Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay [PMID: 22196122]
HUVEC IC50 61 μM Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA [PMID: 9214730]
KB IC50 16.1 μM Cytotoxicity against multi-drug resistant human KB cells overexpressing mdr1 after 3 days [PMID: 18722769]
KB IC50 31.1 μM Cytotoxicity against human KB cells after 3 days [PMID: 18722769]
MV4-11 GI50 5.59 μM Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay [PMID: 23411073]
RS4-11 GI50 40 μM Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay [PMID: 23411073]

Oroxylin A Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Oroxylin A from 3 published references.

Oroxylin A In Vitro Studies

In palmitate-exposed H9c2 cells, 50 µM oroxylin-A for 24 hours increased mitochondrial membrane-potential signal and reduced ROS signals. The authors caution that oroxylin-A is not a very specific sirtuin activator and may have off-target effects. [2]

Oroxylin A did not show chrysin-like p53 acetylation and p21 induction in an MCF7 flavonoid screen at 40 µM for 8 hours. The result is limited to this qualitative immunoblot comparison. [3]

Mitochondrial and oxidative-stress responses in H9c2 cells

Cell-based study · Rat H9c2 cardiomyoblasts exposed to 200 µM palmitate; BSA control and palmitate vehicle comparator [2]

Oroxylin-A co-treatment increased mitochondrial membrane-potential signal and reduced cellular and mitochondrial ROS signals relative to palmitate alone. These are phenotypic responses, without proof of selective SIRT3 engagement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mitochondrial membrane potentialqualitative response Increased relative to palmitate control; figure caption mean ± SEM, n = 3.[2]
Cellular and crude mitochondrial ROSqualitative response Both signals decreased relative to palmitate control; figure caption mean ± SEM, n = 3.[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 µM Oroxylin-A with 200 µM palmitate
Exposure duration
24 h
Method
Cell treatment
Vehicle
DMSO; final volume did not exceed 0.2% (v/v)
Co-treatment
Oroxylin-A alone with palmitate selected. Separate SRT1720, SRT1720 plus Oroxylin-A, and metformin comparisons were included.
Reported limits
Figure captions report n = 3 without defining the replication unit. No direct SIRT3 binding or selectivity assay establishes these phenotypes.
Methods and source locations

Compound reported in the paper: Oroxylin A; Compound label in the paper: Oroxylin-A

Named parent-compound evidence; no salt conversion or validation of the supplied product lot.

Methods 2.1.2–2.1.7; Results 3.11, 3.13; Figures 7A and 9A–B; section 6

Mitochondrial membrane potential: TMRM staining and flow cytometry — Methods 2.1.6; Results 3.11; Figure 7A and caption

Cellular and crude mitochondrial ROS: DCFH-DA and MitoSOX Red fluorescence by flow cytometry — Methods 2.1.3–2.1.4; Results 3.13; Figure 9A–B and caption

Flavonoid comparison reveals a limited p53 response

Cell-based study · MCF7 human breast cancer cells; DMSO negative control, chrysin and adriamycin positive comparisons [3]

Oroxylin A did not show the chrysin-like increase in p53 Lys382 acetylation and p21 in this short-exposure immunoblot screen. This does not exclude other p53 responses at other times or concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
p53 Lys382 acetylation and p21 protein responsequalitative response No chrysin-like induction apparent in the Oroxylin A lane; qualitative blot comparison only.[3]

Literature-Reported Treatment Conditions

Treatment concentration
40 µM
Exposure duration
8 h
Method
Cell treatment
Vehicle
DMSO control; final solvent concentration not stated in the selected experiment
Co-treatment
Single-agent flavonoid comparisons; adriamycin 0.3 µM and chrysin 40 µM were comparison treatments, not combinations.
Reported limits
Figure 4 does not report n, densitometric values or an uncertainty estimate. No quantitative null-effect size is inferred.
Methods and source locations

Compound reported in the paper: Oroxylin A; Compound label in the paper: Oroxylin A

Named parent-compound evidence; no salt conversion or validation of the supplied product lot.

Results 2.3; Figure 4A and caption; Methods 4.3 and 4.11

p53 Lys382 acetylation and p21 protein response: Immunoblotting for K382Ac, p53, p21 with β-actin loading control — Results 2.3; Figure 4A; Methods 4.3

Cellular LDH-A expression and activity in LX2 cells

Cell-based study · Human LX2 hepatic stellate cell line; comparator labeled Control [1]

Oroxylin A reduced LDH-A mRNA, protein abundance and intracellular enzyme activity. This cellular result does not establish inhibition of purified LDH-A or a direct molecular interaction.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LDH-A mRNA, protein and intracellular enzyme activityqualitative response Reduced across the concentration series; 30 and 40 µM marked p < 0.05 or p < 0.01 vs Control. General statistics: mean ± SD from at least triplicate experiments.[1]

Literature-Reported Treatment Conditions

Treatment concentration
20, 30 and 40 µM
Exposure duration
24 h
Method
Cell treatment
Vehicle
DMSO used to dissolve the reagent; final concentration not reported in selected text
Co-treatment
Single-agent concentration series; genetic and galloflavin experiments were read as context but are not adopted claims.
Reported limits
No purified-enzyme IC50 or direct-binding endpoint in this experiment. The statistics section gives at least triplicate experiments without a panel-specific exact n.
Methods and source locations

Compound reported in the paper: Oroxylin A; Compound label in the paper: Oroxylin A

Named parent-compound evidence; no salt conversion or validation of the supplied product lot.

Methods Chemicals and antibodies, Cell culture and transfection, Enzyme activity assay, Statistical analysis; Results Oroxylin a inhibits LDH-A in HSCs; Figure 4a–d

LDH-A mRNA, protein and intracellular enzyme activity: Real-time PCR, immunoblotting, immunofluorescence and cellular enzyme-activity kit — Figure 4a–d and caption; Results Oroxylin a inhibits LDH-A in HSCs; Methods Enzyme activity assay and Statistical analysis

Oroxylin A In Vivo Studies

In high-fructose-fed male rats, oroxylin-A at 10 mg/kg/day intraperitoneally for eight weeks improved ejection fraction and fractional shortening. QT and QTc intervals showed no significant change. The authors reported no synergistic benefit from combining oroxylin-A with SRT1720. [2]

Cardiac function in high-fructose-fed rats

Animal study · Male Sprague–Dawley rats; high-fructose diet (65% kcal from fructose) for 20 weeks, with corn-starch-diet controls [2]

Oroxylin-A improved fractional shortening and ejection fraction relative to high-fructose-diet vehicle controls. LVDd, QT and QTc showed no significant between-group change. The authors did not observe a synergistic benefit of the SRT1720 combination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ejection fraction and fractional shortening; left ventricular internal diameter in diastolequalitative response EF and FS improved (reported p < 0.01 vs high-fructose diet); no significant LVDd change. Figure caption: mean ± SEM, n = 5.[2]
QT and QTc intervalsqualitative response No significant change in any group; mean ± SEM, n = 5 in figure caption.[2]
Combination benefitqualitative response No synergistic effect of SRT1720 plus Oroxylin-A was observed by the authors.[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Daily
Treatment course
8 weeks (weeks 12–20)
Vehicle
PEG400:Tween-80 (90:10)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
High-fructose diet plus Oroxylin-A
10 mg/kg/day
High-fructose diet plus vehicle; corn-starch diet control also includedImproved EF and FS versus high-fructose-diet vehicle group; no significant QT/QTc change in the experimental groups.[2]
High-fructose diet plus Oroxylin-A
Model: Male Sprague–Dawley rats; high-fructose diet (65% kcal from fructose) for 20 weeks, with corn-starch-diet controls
Reported limits: Oroxylin-A supplier-specific lot and purity not established. Figure 2 reports n = 5.
Methods and source locations

Compound reported in the paper: Oroxylin A; Compound label in the paper: Oroxylin-A

Named parent-compound evidence; no salt conversion or validation of the supplied product lot.

Methods 2.2, 2.2.4; Results 3.3–3.4; Figure 2A–D,G–H; Abstract; section 6

Ejection fraction and fractional shortening; left ventricular internal diameter in diastole: M-mode echocardiography; three representative cycles averaged; analyst blinded to treatment — Results 3.3; Figure 2A–D and caption; Methods 2.2.4

QT and QTc intervals: Electrocardiography — Results 3.4; Figure 2G–H and caption

Combination benefit: Comparison within the same animal design; no formal synergy metric adopted — Abstract; Conclusions; Methods 2.2

High-fructose diet plus Oroxylin-A · Methods 2.2 and 2.2.4; Results 3.3–3.4; Figure 2 and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 480-11-5
Formula C16H12O5
Molecular Weight 284.27
Synonyms Oroxyline-A
SMILES
COC1=C(C=C2C(=C1O)C(=O)C=C(O2)C3=CC=CC=C3)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 53 mg/mL (186.44 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Oroxylin A Research References

  1. [1] Feixia Wang, Yan Jia, Mengmeng Li, et al. Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells Cell Communication and Signaling : CCS (2019). PMID: 30744642 DOI: 10.1186/s12964-019-0324-8 Source material
  2. [2] Bugga Paramesha, Mohammed Soheb Anwar, Himanshu Meghwani, et al. Sirt1 and Sirt3 Activation Improved Cardiac Function of Diabetic Rats via Modulation of Mitochondrial Function Antioxidants (2021). PMID: 33668369 DOI: 10.3390/antiox10030338 Source material
  3. [3] Mai Nagasaka, Ryoko Hashimoto, Yasumichi Inoue, et al. Anti-Tumorigenic Activity of Chrysin from Oroxylum indicum via Non-Genotoxic p53 Activation through the ATM-Chk2 Pathway Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry (2018). PMID: 29890668 DOI: 10.3390/molecules23061394 Source material

Publications

3 publications citing this product

  1. Paramesha Bugga, .et al. , Cell Signal, 2022, Jun;94:110309 PMID: 35304284
  2. Bugga Paramesha, .et al. , Antioxidants (Basel), 2021, Feb 24;10(3):338 PMID: 33668369
  3. Mai Nagasaka, .et al. , Molecules, 2018, Jun; 23(6): 1394 PMID: 29890668

Added to your cart

View Cart Checkout
Loading...